There are at least 2 types of cannabinoid receptor, CB 1 and CB 2 , both G protein coupled. CB 1 receptors are expressed predominantly at nerve terminals and mediate inhibition of transmitter release, whereas CB 2 receptors are found mainly on immune cells, their roles including the modulation of cytokine release and of immune cell migration. Endogenous agonists for cannabinoid receptors also exist. These " endocannabinoids " are synthesized on demand and removed from their sites of action by cellular uptake and intracellular enzymic hydrolysis. Endocannabinoids and their receptors together constitute the endocannabinoid system. This review summarizes evidence that there are certain central and peripheral disorders in which increases take place in the release of endocannabinoids onto their receptors and/or in the density or coupling effi ciency of these receptors and that this upregulation is protective in some disorders but can have undesirable consequences in others. It also considers therapeutic strategies by which this upregulation might be modulated to clinical advantage. These strategies include the administration of (1) a CB 1 and/or CB 2 receptor agonist or antagonist that does or does not readily cross the blood brain barrier; (2) a CB 1 and/or CB 2 receptor agonist intrathecally or directly to some other site outside the brain; (3) a partial CB 1 and/or CB 2 receptor agonist rather than a full agonist; (4) a CB 1 and/or CB 2 receptor agonist together with a noncannabinoid, for example, morphine or codeine; (5) an inhibitor or activator of endocannabinoid biosynthesis, cellular uptake, or metabolism; (6) an allosteric modulator of the CB 1 receptor; and (7) a CB 2 receptor inverse agonist.
A BSTRACT
There are at least 2 types of cannabinoid receptor, CB 1 and CB 2 , both G protein coupled. CB 1 receptors are expressed predominantly at nerve terminals and mediate inhibition of transmitter release, whereas CB 2 receptors are found mainly on immune cells, their roles including the modulation of cytokine release and of immune cell migration. Endogenous agonists for cannabinoid receptors also exist. These " endocannabinoids " are synthesized on demand and removed from their sites of action by cellular uptake and intracellular enzymic hydrolysis. Endocannabinoids and their receptors together constitute the endocannabinoid system. This review summarizes evidence that there are certain central and peripheral disorders in which increases take place in the release of endocannabinoids onto their receptors and/or in the density or coupling effi ciency of these receptors and that this upregulation is protective in some disorders but can have undesirable consequences in others. It also considers therapeutic strategies by which this upregulation might be modulated to clinical advantage. These strategies include the administration of (1) a CB 1 and/or CB 2 receptor agonist or antagonist that does or does not readily cross the blood brain barrier; (2) a CB 1 and/or CB 2 receptor agonist intrathecally or directly to some other site outside the brain; (3) a partial CB 1 and/or CB 2 receptor agonist rather than a full agonist; (4) a CB 1 and/or CB 2 receptor agonist together with a noncannabinoid, for example, morphine or codeine; (5) an inhibitor or activator of endocannabinoid biosynthesis, cellular uptake, or metabolism; (6) an allosteric modulator of the CB 1 receptor; and (7) a CB 2 receptor inverse agonist.
INTRODUCTION
Mammalian tissues are now known to express at least 2 types of cannabinoid receptor, both of which are G-protein coupled. 1 , 2 These are CB 1 receptors, cloned in Tom Bonner ' s laboratory in 1990 (Matsuda et al 3 ) , and CB 2 receptors, cloned by Sean Munro in 1993. 4 Although CB 1 receptors are expressed by certain nonneuronal cells and tissues, for example, the pituitary gland, immune cells, and reproductive tissues, they are found predominantly at central and peripheral nerve terminals where they mediate inhibition of transmitter release. CB 2 receptors occur mainly on immune cells, their functions including the modulation, both within and outside the central nervous system, of cytokine release and immune cell migration. Thus, one common role of CB 1 and CB 2 receptors appears to be the regulation of ongoing release of chemical messengers, CB 1 receptors mainly from neurones and CB 2 receptors from immune cells. The fi nding that mammalian tissues express cannabinoid receptors was followed by the discovery of endogenous ligands for these receptors ( Endocannabinoids section). These endogenous cannabinoids or endocannabinoids are all eicosanoids, 2 notable examples being N -arachidonoylethanolamine (anandamide) and 2-arachidonoyl glycerol. Endocannabinoids together with cannabinoid CB 1 and CB 2 receptors constitute the endocannabinoid system.
The discovery of the endocannabinoid system has prompted research directed at establishing its physiological and pathophysiological roles. This research has provided evidence fi rst, that there are certain disorders in which endocannabinoid levels, cannabinoid receptor density, and/or cannabinoid receptor coupling effi ciency increase in particular tissues, and second, that this upregulation of the endocannabinoid system often leads to a suppression of unwanted signs and symptoms, and so is autoprotective. The main objectives of this review are to summarize the evidence that the endocannabinoid system can be protective, and then to go on to consider possible therapeutic strategies by which such protection might best be exploited in the clinic. These are strategies in which endocannabinoid-induced protection is mimicked with directly acting CB 1 and/or CB 2 receptor agonists or in which it is augmented with drugs expected to delay the disappearance of endocannabinoids following E626 their endogenous release or to induce an allosteric enhancement of cannabinoid receptor activation by released endocannabinoids. Evidence that the endocannabinoid system may sometimes be responsible for the production of undesirable effects is also briefl y discussed. The review begins with short overviews of fi rst, the pharmacological actions of important cannabinoid receptor ligands; second, the processes by which endocannabinoids are produced and then removed from their sites of action; and third, the progress that has been made to date in the development of drugs that can selectively inhibit one or other of these removal processes.
CANNABINOID RECEPTOR LIGANDS
Several ligands that bind selectively to cannabinoid receptors are now available. 1 , 2 These fall essentially into 2 categories: the exogenous cannabinoids that are found in cannabis or have been designed and synthesized by chemists and the endogenous cannabinoids that occur naturally in mammalian tissues.
Exogenous Ligands
As detailed elsewhere, 1 , 2 a large number of CB 1 and CB 2 receptor agonists and antagonists have now been developed. Among the agonists are several compounds that bind more or less equally well to CB 1 and CB 2 receptors, examples being the " classical " cannabinoids, ⌬ 9 -THC and ( -)-11-hydroxy-⌬ 8 -THC-dimethylheptyl (HU-210), the " nonclassical " cannabinoid, CP55940, and the aminoalkylindole cannabinoid, R -(+)-WIN55212, which has marginally greater CB 2 than CB 1 affi nity. Of these nonselective agonists, HU-210, CP55940, and R -(+)-WIN55212 have the highest CB 1 and CB 2 relative intrinsic activities, and HU-210 has the highest affi nity for both CB 1 and CB 2 receptors. ⌬ 9 -THC, which is the main psychotropic constituent of cannabis, has lower CB 1 and CB 2 affi nities and relative intrinsic activities than these other cannabinoids. Indeed, at both receptor types, ⌬ 9 -THC exhibits the mixed agonist-antagonist properties that are typical of a partial agonist. Another cannabis constituent, the classical cannabinoid cannabinol, also behaves as a partial agonist, at least at CB 1 receptors. 5 Agonists with signifi cant selectivity for CB 1 or CB 2 receptors have also been developed. Notable CB 1 -selective agonists include the eicosanoids R -(+)-methanandamide, arachidonyl-2 ' -chloroethylamide (ACEA), arachidonylcyclopropylamide (ACPA), and O-1812, which are all analogs of the endocannabinoid, anandamide ( Endocannabinoids section). CB 2 -selective agonists include L-759633, L-759656, and JWH-133, all structural analogs of ⌬ 9 -THC; other notable examples are the nonclassical cannabinoid, HU-308, and the aminoalkylindoles, JWH-015 and AM1241.
Turning now to cannabinoid receptor antagonists, the compounds most commonly used in research are the CB 1 -selective SR141716A, AM251, and AM281 and the CB 2 -selective SR144528 and AM630. These are usually all classifi ed as inverse agonists since they can, in at least some cannabinoid receptor-containing systems, produce effects by themselves that are opposite in direction from those produced by agonists for these receptors. 6 It is thought that they may produce these inverse cannabimimetic effects by shifting cannabinoid receptors from a constitutively active " on " state to one or more constitutively inactive " off " states. This putative mechanism relies on the assumption that cannabinoid receptors can exist in a constitutively active state in which they undergo some degree of spontaneous coupling to their effector mechanisms even in the absence of an endogenously released or exogenously added agonist. " Neutral " antagonists have also been developed. 6 These share the ability of the inverse agonists to block responses to cannabinoid receptor agonists but lack the apparent ability of inverse agonists to produce inverse cannabimimetic effects in cannabinoid receptor-containing systems in the absence of any endogenously released or exogenously added cannabinoid receptor agonist. Neutral antagonists are, however, expected to share the ability of CB 1 and CB 2 receptor inverse agonists to produce inverse cannabimimetic effects in tonically active biological systems when this tonic activity arises from ongoing endocannabinoid release onto cannabinoid receptors.
There is evidence that some established exogenous cannabinoid receptor agonists and antagonists have non-CB 1 , non-CB 2 pharmacological targets. 2 , 6 , 7 These include TRPV1 (vanilloid VR1) receptors for some eicosanoid agonists (see also Endocannabinoids section), adenosine A 1 receptors for SR141716A and AM251, and possibly also the following:
• central putative TRPV1-like receptors for CP55940, R -(+)-WIN55212 and SR141716A but not AM251;
• central putative non-CB 1 , non-CB 2 , non-TRPV1 G protein-coupled receptors for R -(+)-WIN55212 but not ⌬ 9 -THC, HU-210, or CP55940;
• putative non-CB 1 , non-CB 2 , non-TRPV1 receptors on perivascular sensory neurons for ⌬ 9 -THC and cannabinol but not HU-210 or CP55940;
• putative non-I 1 , non-I 2 imidazoline receptors for CP55940, R -(+)-WIN55212, and SR141716A;
• putative abnormal-cannabidiol receptors on mesenteric arteries for R -(+)-methanandamide and SR141716A but not for ⌬ 9 -THC or R -(+)-WIN55212;
• gap junctions and L-type Ca 2+ channels for SR141716A;
• Ca 2+ -activated (BK Ca ) and ATP-sensitive potassium channels for SR141716A; and 8 Whether there are also allosteric sites on CB 2 receptors remains to be established.
Endocannabinoids
The most investigated of the endocannabinoids have been the polyunsaturated fatty acid amide, N -arachidonoylethanolamine (anandamide), and the polyunsaturated monoacylglycerol, 2-arachidonoyl glycerol. 1 , 2 , 9 Of these, anandamide has marginally greater CB 1 than CB 2 affi nity and, like the exogenous cannabinoid ⌬ 9 -THC, exhibits relatively low effi cacy at CB 1 and CB 2 receptors, behaving as a partial agonist at both receptor types. As to 2-arachidonoyl glycerol, this has been found in several investigations to have affi nities for CB 1 and CB 2 receptors similar to those of anandamide but to exhibit higher CB 1 and CB 2 effi cacy than anandamide. There has, however, been one recent investigation with human CB 1 receptor-containing tissue in which 2-arachidonoyl glycerol was found both to exhibit lower CB 1 receptor affi nity than anandamide and to lack detectable CB 1 receptor effi cacy at concentrations of up to 10 µM. 10 It is likely that anandamide and/or 2-arachidonoyl glycerol have neuromodulatory roles (eg, by serving as retrograde synaptic messengers) and immunomodulatory roles (eg, through the regulation of cytokine release and immune cell migration). 1 , 2 , 11-13 It is also likely that both these endocannabinoids play a part in certain pathological processes both within and without the central nervous system.
Cannabinoid CB 1 and CB 2 receptors are not the only pharmacological targets for anandamide. 2 , 7 , 14-16 Thus, it is generally accepted that the TRPV1 receptor is activated by anandamide and by synthetic analogs of this endocannabinoid such as methanandamide, arachidonyl-2 ' -chloroethylamide, and N -(4-hydroxybenzyl)arachidonoylamine (AM404), although not by 2-arachidonoyl glycerol or by noneicosanoid cannabinoid receptor agonists such as R -(+)-WIN55212, CP55940, or HU-210. As detailed elsewhere, 2 , 7 additional targets that have been proposed for anandamide include
• central putative non-CB 1 , non-CB 2 , non-TRPV1 G protein-coupled receptors that are also activated by R -(+)-WIN55212;
• putative non-CB 1 , non-TRPV1 receptors on neurons of the small intestine;
• putative non-I 1 , non-I 2 imidazoline receptors that are also activated by CP55940 and R -(+)-WIN55212;
• putative abnormal-cannabidiol receptors on mesenteric arteries that are also activated by R -(+)-methanandamide but not by 2-arachidonoyl glycerol;
• putative non-CB 1 , non-CB 2 , non-TRPV1 receptors on coronary arteries;
• allosteric sites on muscarinic M 1 and M 4 receptors and on 5-HT 3 receptors that are also activated by certain exogenous cannabinoids; and
• allosteric sites on glutamate GLU A1 and GLU A3 receptors.
Other endocannabinoids are the anandamide analogs, dihomo-␥ -linolenoylethanolamide, docosatetraenoylethanolamide, and possibly the CB 1 -selective agonist 2-arachidonylglyceryl ether (noladin ether). 9 N -arachidonoyl dopamine, N -oleoyl dopamine, and oleamide may also be endocannabinoids as there are reports that these endogenous compounds can bind to CB 1 receptors with K i values that are in the midnanomolar ( N -arachidonoyl dopamine) or low micromolar range. 9 , 17 , 18 N -arachidonoyl dopamine can induce both antinociception in the mouse hot-plate test and thermal hyperalgesia, is distributed differently from anandamide in the brain, and shares the ability of anandamide to activate TRPV1 receptors. 9 , 17 N -oleoyl dopamine is also a TRPV1 receptor agonist. Indeed, it activates these receptors with particularly high potency and has also been found to induce both thermal hyperalgesia and allodynia. 9 The monounsaturated fatty acid amide, oleamide, has been shown to activate CB 1 receptors at concentrations above 10 or 100 nM, to block gap junction-mediated cell-cell communication, and to increase food intake, and has been postulated to be involved in sleep regulation. 9 , 18 One other endogenous fatty acid amide that interacts with cannabinoid receptors at concentrations in the low micromolar range is O -arachidonoylethanolamine (virodhamine). 9 In one investigation this ligand was found to activate CB 2 receptors but to exhibit either partial agonist or antagonist activity at CB 1 receptors, 19 whereas in another it behaved as a CB 1 receptor antagonist/inverse agonist. 10 
THE FATE OF ENDOCANNABINOIDS AND ITS MODULATION BY DRUGS

The Biosynthesis and Fate of Endocannabinoids
The biosynthesis of anandamide takes place on demand in response to elevations of intracellular calcium. The imme diate precursor to anandamide is N -arachidonoyl phosphatidylethanolamine, which is formed from phosphatidylcholine and phosphatidylethanolamine and is
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converted to anandamide by the action of N -arachidonoyl phosphatidylethanolamine-phospholipase D. 16 , 20 Anandamide is removed from its sites of action by cellular uptake processes that may involve a transmembrane carrier protein, membrane-associated binding proteins, and/or simple diffusion. 21 It is then metabolized intracellularly. In most tissues, this metabolism is catalyzed by fatty acid amide hydrolase (FAAH), 16 , 22 , 23 an enzyme that in central neurons is located mainly on the cytosolic surfaces of smooth endoplasmic reticulum cisternae and mitochondria. 24 Anandamide is also sometimes metabolized by another intracellular enzyme, palmitoylethanolamide-preferring acid amidase (PAA), 22 , 25 , 26 and indeed, there is evidence that it is PAA rather than FAAH that is primarily responsible for deactivating anandamide in the mouse duodenum. 27 Other enzymes that can metabolize anandamide are cyclooxygenase-2, lipoxygenases, and cytochrome P450. 28 Like anandamide, 2-arachidonoyl glycerol is not stored but rather synthesized on demand in a manner that can be triggered by elevations of intracellular calcium. 16 , 20 Its synthesis depends on the conversion of 2-arachidonate-containing phosphoinositides to diacylglycerols (DAGs), which are then converted to 2-arachidonoyl glycerol by the action of DAG lipase. Also, like anandamide, 2-arachidonoyl glycerol is thought to be removed from its sites of action by cellular uptake and then to be metabolized intracellularly. 16 , 20 , 28 Although 2-arachidonoyl glycerol can readily be metabolized by FAAH as well as by cyclooxygenase-2 and lipoxygenases, there is evidence that the enzyme mainly responsible for its metabolism in vivo may be monoacyl glycerol (MAG) lipase. 20 , 22 , 29 , 30 FAAH, MAG lipase, and cannabinoid CB 1 receptors have broadly similar distribution patterns, at least within some brain areas. 24 It is noteworthy, however, that while MAG lipase and cannabinoid CB 1 receptors are located mainly presynaptically in these brain areas, FAAH is found mainly postsynaptically in somata and dendrites of principal neurons. Unlike polyunsaturated fatty acid amides, mono-unsaturated and saturated fatty acid amides are thought to be poor substrates for the putative anandamide transporter. 27 In contrast, cellular uptake may be the main means by which noladin ether is removed from its site of action as this putative endocannabinoid is considered not to be a likely substrate for enzymic hydrolysis. 31 N -oleoyl dopamine is also thought to be recognized by the putative anandamide transporter and to be only a poor FAAH substrate. 9 However, 3 other putative endocannabinoids, oleamide, N -arachidonoyl dopamine, and virodhamine, all appear to be reasonable FAAH substrates. 23 Several endogenous fatty acid amides, in addition to anandamide, are metabolized by FAAH. 22 , 23 , 26 , 27 These include not only polyunsaturated fatty acid amides such as N -arachidonoyl dopamine but also a range of mono-unsaturated and saturated compounds. One endogenous saturated fatty acid amide that serves as a substrate for FAAH, and also for PAA, is palmitoylethanolamide. 22 , 25 This has antiinfl ammatory and antinociceptive properties, can potentiate anandamide-induced antinociception and TRPV1 receptor activation, lacks signifi cant affi nity for CB 1 or CB 2 receptors, and is thought to be an agonist for the PPAR-␣ receptor and possibly also for a putative " CB 2 -like " receptor. 7 , 26 , 32 A second pharmacologically active endogenous substrate of FAAH and PAA is the mono-unsaturated fatty acid amide, oleoylethanolamide, which can inhibit both anandamide cellular uptake and metabolism. Like palmitoylethanolamide, oleoylethanolamide can activate PPAR-␣ receptors and has negligible affi nity for CB 1 or CB 2 receptors. 9 There is evidence that oleoylethanolamide serves as a satiety hormone, that it is released in the upper small intestine in response to food intake, and that it induces hypophagia by acting through intestinal PPAR-␣ receptors to activate vagal sensory afferent neurons that innervate higher brain structures involved in the control of energy balance. 26 , 27 Oleoylethanolamide is also a TRPV1 receptor agonist. 9 Other pharmacologically active endogenous fatty acid amides include linoleamide, which is a FAAH substrate, may be involved in sleep regulation, and does not interact appreciably with cannabinoid receptors; N -arachidonoyl serine, which activates the putative abnormal-cannabidiol receptor; and N -palmitoyl dopamine and N -stearoyl dopamine, which potentiate anandamide at TRPV1 receptors but do not inhibit its cellular uptake or its metabolism by FAAH. 9 Two other endogenous ligands of interest are N -arachidonoyl glycine and the unsaturated fatty acid amide, linoleoylethanolamide, as both have been reported to inhibit FAAH. It has also been found that N -arachidonoyl glycine has antinociceptive and anti-edema activity, that it lacks signifi cant affi nity for cannabinoid CB 1 receptors, and that it is a FAAH substrate. 9 , 23 , 33 Finally, it is noteworthy that some effects of endogenously released anandamide and 2-arachidonoyl glycerol may be enhanced through an " entourage effect " that relies on the corelease of other endogenous fatty acid derivatives. These derivatives include palmitoylethanolamide and oleamide, which can potentiate anandamide, and 2-linoleyl glycerol and 2-palmitoyl glycerol, which can potentiate 2-arachidonoyl glycerol. 2
Inhibitors of Endocannabinoid Cellular Uptake and Intracellular Metabolism
The fi nding that the actions of anandamide and 2-arachidonoyl glycerol are terminated by cellular uptake and intracellular enzymic hydrolysis has been followed by the discovery of several drugs that will inhibit one or other of these processes. 16 • N -(3-furylmethyl)arachidonoylamine (UCM707) that inhibits anandamide cellular uptake (K i = 0.8, 25, 41, or >100 µM), is a FAAH substrate and inhibitor (IC 50 = 30 µM or >100 µM), binds to CB 1 (K i = 4.7 µM) and CB 2 receptors (K i = 67 nM), and lacks appreciable affi nity for TRPV1 receptors (K i > 5 µM). 48 , 50 , 51 AM374 is an analog of the irreversible serine protease inhibitor, phenylmethylsulphonyl fl uoride (PMSF), which itself inhibits both FAAH (IC 50 = 290 nM to 15 µM) and MAG lipase (IC 50 = 155 µM or >500 µM). 23 MAG lipase inhibitors with suffi cient potency and selectivity for use as pharmacological tools have yet to be developed. 23 Results obtained with the FAAH and cellular uptake inhibitors listed above should be interpreted with particular caution as the pharmacological characterization of these compounds is far from complete. An added complication for some of these inhibitors is that they can activate TRPV1 receptors, an action that is known to stimulate anandamide biosynthesis, presumably by increasing the intracellular concentration of calcium, 16 and that will most likely also stimulate the biosynthesis of other endocannabinoids including 2-arachidonoyl glycerol. Based on the available data, compounds that currently show greatest promise as pharmacological tools are AM374, URB532, URB597, and OL-135 for FAAH inhibition, and OMDM-1 for inhibition of the cellular uptake of anandamide. • lumbar spinal cord in a mouse model of amyotrophic lateral sclerosis ( Table 2 );
• basal ganglia in a rat model of Parkinson ' s disease ( Table 2 );
• ventral mesencephalon in a rat model of Huntington ' s disease ( Table 2 );
• periaqueductal gray in a rat model of infl ammatory pain ( Table 2 );
• urinary bladder in a rat model of painful hemorrhagic cystitis ( Table 2 );
• hypothalamus and uterus in mouse models of obesity ( Table 2 );
• cardiovascular tissue in experimental models of septic shock, cardiogenic shock, and biliary cirrhosis ( Table 3 );
• small intestine in rodent models of paralytic ileus, ileitis, and secretory diarrhea ( Table 3 ) ; and
• lesioned brain areas in rat models of cerebral ischemia and excitotoxicity ( Table 4 ).
In some of these investigations, tissue levels of 2-arachidonoyl glycerol were also monitored. These were found to increase in human colorectal and pituitary adenomas or carcinomas ( Table 1 ) ; in bone cement implantation syndrome ( Table 1 ) ; in mouse models of multiple sclerosis, amyotrophic lateral sclerosis, aversive memory extinction, and obesity ( Tables 2 and 3 ) ; in rat models of hepatic ischemia-reperfusion injury, myocardial infarction, and ileitis ( Table 4 ) ; and in a model of cardiogenic shock ( Table 3 ) . Usually these increases were detected in the same tissues as those in which increases in anandamide levels occurred. However, there have been at least 2 instances in which increases in anandamide and 2-arachidonoyl glycerol were found to have taken place in different cell-types: in a mouse model of septic shock 113 and in experiments with human cancer cells 73 ( Tables 1 and 3 ). There have also been a few instances in which increases in anandamide levels were found not to have been paralleled by any detectable increases in 2-arachidonoyl glycerol ( Tables 1 , 2 , 3 , and 4 ) or in which an increase in 2-arachidonoyl glycerol was not accompanied by any increase in anandamide ( Tables 2 ,  3 , and 4 ). Increased levels of 2-arachidonoyl glycerol in brain tissue have sometimes been observed in experiments in which anandamide levels were not also monitored, for example, in experiments with a mouse model of closed head injury and with a rat model of excitotoxicity ( Table 4 ) .
Increases in tissue levels of anandamide and 2-arachidonoyl glycerol are most likely usually triggered by increases in intracellular calcium. However, there is evidence that these increases are sometimes further modulated by changes in the ability of tissues to synthesize these compounds and/or to dispose of them by cellular uptake or subsequent enzymic degradation. Thus, for example, in a mouse model of obesity in which increases in uterine levels of both anandamide and 2-arachidonoyl glycerol were detected, these increases were found to be accompanied by a decrease in uterine tissue both of FAAH and MAG lipase activity and of anandamide transport across membranes 104 ( Table 2 ). An increase in uterine DAG lipase activity was noted as well, suggesting that the increased uterine levels of 2-arachidonoyl glycerol observed in these experiments were partly attributable to an increase in the capacity of the uterus to synthesize this endocannabinoid. A decrease in FAAH activity has also been observed to accompany increases in anandamide levels in the peripheral lymphocytes of women with implantation failure ( Table 1 ) and in rat striatal tissue in a model of Parkinson ' s disease ( Table  2 ) . Also observed in these rat experiments was a decrease in anandamide cellular uptake. However, in experiments using a lipopolysaccharide (LPS) model of endotoxic shock, in one study LPS-induced increases in anandamide levels were reported to be paralleled by a decrease in the gene expression and activity of FAAH (in human peripheral lymphocytes), 115 while in another study, in which a much lower concentration of LPS was used, increases in anandamide levels were found to be paralleled by an increase in the expression and activity of this enzyme (in mouse macrophages) 114 ( Table 3 ). In the second of these investigations, increases were also detected in the activities of 2 enzymes that can catalyze anandamide biosynthesis ( N -acyltranferase and N -arachidonoyl phosphatidylethanolamine-phospholipase D). An increase in FAAH activity has also been detected in the small intestine of mice in which intestinal infl ammation and increased motility had been induced by orally administered croton oil 117 ( Table 3 ) .
In these experiments, high levels of anandamide (and 
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2-arachidonoyl glycerol) were detected in the small intestine of both croton oil-treated and control mice. Some increases in anandamide tissue levels take place in the absence of changes in FAAH expression or activity. Thus, for example, in experiments with human colorectal cancer biopsies ( Table 1 ) and with mouse models of diarrhea and paralytic ileus ( Table 3 ) , elevations in anandamide levels observed in the cancerous tissue and in mouse small intestine were not associated with any detectable changes in FAAH expression or activity.
In some disorders or animal models in which endocannabinoid tissue concentrations have been reported to be high, elevated expression levels and/or densities of cannabinoid CB 1 receptors have also been detected. Such upregulation of the CB 1 receptor has been observed in the following:
• postmortem cerebral cortical tissue of suicide victims ( Table 1 ),
• tissue from humans with advanced liver cirrhosis ( Table 1 ),
• brain tissue in a rat model of traumatic head injury ( Table 4 ) , and
• small intestine in mouse models of intesti nal infl ammation, secretory diarrhea, and paralytic ileus ( Table 3 ).
Increases in CB 1 receptor density have also sometimes been detected in experiments in which no increases in endocannabinoid levels were observed or no measurements of endocannabinoid tissue concentrations made. These increases in receptor density were detected in the following:
• brain tissue taken postmortem from patients with schizophrenia or Parkinson ' s disease ( Table 1 ),
• the striatum in marmoset and rat models of Parkinson ' s disease ( Table 2 ),
• the spinal cord in a rat model of neuropathic pain ( Table 2 ),
• cortical neurons in a rat model of focal cerebral ischemia ( Table 4 ),
• the hippocampus in a rat febrile seizure model ( Table 4 ),
• the colon in a mouse model of colitis ( Table 3 ),
• mesenteric arteries in a rat model of cirrhosis ( Table 3 ) , and
• human prostate cancer cells ( Table 1 ) .
It is noteworthy that spontaneously hypertensive rats have been reported to exhibit increased CB 1 receptor density in myocardium and aorta but a decrease in myocardial anandamide levels 111 ( Table 3 ) . Conversely, excitotoxicity induced by N -methyl-D-aspartate (NMDA) in rats has been found to provoke not only a rise in anandamide concentrations but a fall in CB 1 receptor density and expression level in some brain areas ( Table 4 ) . A fall in CB 1 receptor density has also been detected in cerebral cortex and caudate putamen in a rat model of multiple sclerosis ( Table 2 ). However, in this investigation, the reduced population of cannabinoid receptors was found to signal with increased effi ciency. 
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Increases in the effi ciency of CB 1 receptor signaling have also been observed in postmortem brain tissue of patients who had suffered from Parkinson ' s disease or were suicide victims ( Table 1 ) and in the striatum in a marmoset model of Parkinson ' s disease ( Table 2 ) . Additional examples of human disorders or of animal models of disorders in which signs of downregulation rather than upregulation of the endocannabinoid system have been observed are to be found in Tables 1 to 4 .
It is likely that expression levels of CB 2 receptors also change in certain disorders. Indeed, Zhang et al 100 have found that when signs of neuropathic pain were produced in rats by sciatic nerve ligation, nonneuronal CB 2 -expressing cells became detectable in the lumbar spinal cord. These cells were probably activated microglia that had migrated into this region of the cord. CB 2 expression was detectable only in certain regions of the dorsal and ventral horns, the precise distribution pattern of these receptors within the spinal cord varying 
Extinction of aversive memories (mouse amygdala)
Age: (a) rat entorhinal and temporal cortices and (b) rat postrhinal cortex immunodefi ciency virus-induced encephalitis but not in samples from control animals 81 (see also Finally, it is important to bear in mind that changes in endocannabinoid tissue levels or in the expression level or density of cannabinoid receptors seems to take place in response not only to certain pathological insults but also to some nonpathological processes or stimuli such as fasting, feeding, stress, aging, and exercise ( Tables 2 and 3 ) .
EVIDENCE THAT THE ENDOCANNABINOID SYSTEM IS AUTOPROTECTIVE
There is evidence not only that tissue concentrations of endocannabinoids, cannabinoid receptor density and/or cannabinoid receptor coupling effi ciency increase in a range of different disorders but also that these increases serve to reduce the severity of signs and symptoms of some of these disorders or even to oppose disease progression. Support for the hypothesis that the endocannabinoid system has such an " autoprotective " role has so far come mainly from experiments concerned with pain, multiple sclerosis, cancer, intestinal, mental and cardiovascular disorders, excitotoxicity, traumatic head injury, and Parkinson ' s disease.
Pain
Reports are emerging that FAAH inhibitors such as OL-135, URB532, URB597, and N -arachidonoylglycine are antinociceptive in various rodent models of pain. These models are the formalin paw test of persistent infl ammatory pain 38 , 39 in which it is already known that central nervous system (CNS) levels of anandamide rise above control values in response to the formalin ( Table 2 ) , and the tail-immersion and hot-plate tests of acute thermal pain. 37 , 38 , 132 There are reports too that the endocannabinoid cellular uptake inhibitors, OMDM-2 and VDM11, produce antinociception in the rat hot-plate test. 133 That the antinociception induced by inhibitors of FAAH or endocannabinoid cellular uptake is mediated by endogenous fatty acid ethanolamides is supported by several fi ndings. These include the observations that OL-135, URB597, and N -arachidonoylglycine elevate endogenous levels of these amides in rodents 37 , 38 , 134 and that exogenously administered anandamide can be potentiated by OL-135 in the mouse tail-immersion test 38 and by AM404 in the mouse hot-plate test. 44 Also consistent with this hypothesis are the fi ndings fi rst, that mice from which FAAH has been genetically deleted (FAAH − / − mice) exhibit reduced sensitivity to noxious stimuli when these are applied in the tail-immersion, hot-plate, or formalin paw test or in the carrageenan model of infl ammatory pain 135 , 136 ; and second, that FAAH − / − mice have elevated tissue levels of anandamide and other fatty acid ethanolamides and exhibit greater sensitivity than wildtype mice to the antinociceptive effect of exogenously administered anandamide. 135 Some experiments have been performed with transgenic (FAAH-NS) mice that express FAAH only within the nervous system. These differ from FAAH − / − mice in not exhibiting enhanced levels of anandamide and other fatty acid ethanolamides in the CNS or reduced nociception in the tail-immersion or hot-plate plate test. 137 Consequently, it is likely that signs of hypoalgesia in these tests that are observed in FAAH − / − mice or are induced by FAAH or endocannabinoid cellular uptake inhibitors in wild-type mice depend on the activation of targets located in the nervous system. It is also likely that these targets are mainly or wholly cannabinoid CB 1 receptors. Thus, Kathuria et al 37 found that the antinociceptive effects of URB532 and URB597 in the mouse hot-plate test were attenuated by SR141716A at a dose that by itself had no effect on nociception. Similarly, it was found by Lichtman et al 38 that SR141716A attenuated OL-135 induced-antinociception in mice in the tail-immersion, hot-plate, and formalin paw tests. None of the FAAH inhibitors used in these 2 investigations exhibited signifi cant affi nity for CB 1 (or CB 2 ) receptors, suggesting that these inhibitors did not produce antinociception by activating cannabinoid receptors directly. It has also been found that after they have been injected with SR141716A, FAAH − / − mice no longer exhibit hypoalgesic responses to noxious stimuli in the tail-immersion test, the hot-plate test, or the formalin paw test (both phases). 135 , 136 There is good evidence that CB 2 receptor activation can induce antinociception in the second phase of the formalin paw test (see below). Even so, it is unlikely that the signs of hypoalgesia that are exhibited by FAAH − / − mice in this pain model are mediated by CB 2 receptors as the ability of SR141716A to eliminate these signs in such animals is not shared by SR144528. 136 The concept that cannabinoid CB 1 receptors can mediate antinociception produced by inhibitors of FAAH or endocannabinoid cellular uptake or by genetic deletion of FAAH is consistent with several fi ndings that have been extensively reviewed elsewhere. 20 , 138-140 Briefl y, these fi ndings are fi rst, that CB 1 receptors are located on pain pathways in the brain and spinal cord and on the central and peripheral terminals of primary afferent neurons that mediate both neuropathic and nonneuropathic pain, and second, that cannabinoid receptor agonists can induce signs of antinociception when injected either systemically or directly onto a CB 1 receptorexpressing region of a pain pathway. CB 1 receptor agonists exhibit antinociceptive activity in a wide range of experimental pain models and this antinociception has often been found to be antagonized by SR141716A, albeit sometimes in models in which this antagonist produces signs of hyperalgesia when administered by itself. This hyperalgesia could refl ect either antagonism of endocannabinoids released onto CB 1 receptors or an ability of SR141716A to reduce the extent to which CB 1 receptors couple spontaneously to their effector mechanisms ( Exogenous Ligands section) or both of these actions. Since SR141716A-induced inverse agonism is expected to occur particularly in tissues in which there is a relatively high expression of CB 1 receptors, it is noteworthy that CB 1 receptor expression levels in the spinal cord increase in a rat model of neuropathic pain in which SR141716A has been found to be hyperalgesic 99 , 141 (see also Table 2 ).
That CB 1 receptors have a role in pain perception is also supported by the results from experiments in which antisense methods have been used to achieve a " knockdown " of CB 1 receptors in the brain or spinal cord. [142] [143] [144] Additional support comes from fi ndings that mice from which the CB 1 receptor has been genetically deleted (CB 1 − / − mice) exhibit reduced antinociception following a forced swim in water at 34°C 145 and increased tactile sensitivity. 146 Unexpectedly though, there are also reports that compared with wild-type animals, CB 1 − / − mice exhibit either no differences in nociceptive behavior in hot-plate, tail-immersion, tail-fl ick, tailpressure, or abdominal-stretch tests [146] [147] [148] or even signs of hypoalgesia in the hot-plate test and the fi rst phase of the formalin paw test. 148 There is evidence that CB 2 receptors can also mediate analgesia. Thus, for example, when administered systemically to rats or mice the CB 2 -selective agonists HU308, GW405833, and AM1241 have all been found to exhibit antinociceptive activity in various pain models in a manner that is opposed by a CB 2 -selective antagonist. Such apparent CB 2 -mediated antinociception has been observed for HU308 in the second phase of the mouse formalin paw test, 149 for GW405833 in rat carrageenan and rat and mouse Freund ' s complete adjuvant models of infl ammatory pain and in rat models of neuropathic and incisional pain, 150 , 151 and for AM1241 in rat models of allodynia and of thermal and infl ammatory pain and in mouse and rat models of neuropathic pain. 146 , 152-155 It is unlikely that these CB 2 -selective agonists were also activating CB 1 receptors, as AM1241 was no less effective in reducing signs of neuropathic pain in CB 1 − / − mice than in wild-type animals 146 and as HU-308 and AM1241 were not antagonized by CB 1 -selective antagonists. It is possible that CB 2 receptors that mediate antinociception are located on nonneuronal cells in the skin and that, when activated, these receptors modulate the endogenous release of molecules that target peripheral nociceptors. 152 Indeed, evidence has recently emerged that suggests that one mechanism by which CB 2 selective agonists such as AM1241 produce antinociception, at least in a rat model of thermal pain, may be by stimulating the release of ␤ -endorphin from CB 2 -expressing cells in the skin such as keratinocytes onto -opioid receptors located on the terminals of primary afferent neurons. 156 However, it would be premature to exclude other possibilities, for example, that CB 2 receptors can also be expressed by sensory neurons 157 and that such CB 2 receptors, or indeed microglial CB 2 receptors that appear in the spinal cord after nerve injury 100 (see also Table 2 ), can mediate antinociceptive effects. It also remains possible that CB 2 -selective agonists can produce antinociception in at least some pain models by activating " CB 2 -like " receptors, putative receptors at which the endogenous fatty acid amide palmitoylethanolamide may induce hypoalgesia (reviewed elsewhere 7 , 139 ).
In some pain models, signs of hypoalgesia that seem to be produced by endogenously released endocannabinoids appear to be entirely CB 1 receptor mediated. However, there is also some evidence that antinociception may sometimes be induced instead by endogenous activation of CB 2 or (CB 2 -like) receptors. Thus, in FAAH − / − mice, there is an elevation in the tissue levels of palmitoylethanolamide, 135 which may produce antinociception by acting on a CB 2 -like receptor, and in the carrageenan model of infl ammatory pain, although not in the formalin paw test (see preceding paragraph), these knockout mice exhibit signs of hypoalgesia that are not reduced by SR141716A but are lessened, albeit only partially, by SR144528. 136 It has also been reported that URB597 decreases carrageenan-induced mouse paw edema in an SR144528-sensitive manner. 158 Moreover, when administered by itself, this CB 2 -selective antagonist has been found to produce signs of hyperalgesia in rats both in the carrageenan model 150 and in the fi rst phase of the formalin paw test. 159 However, there are also several reports that CB 2 receptor antagonists are not hyperalgesic in these rat models of infl ammatory pain or in models of allodynia or thermal pain. 152-155 , 160 A CB 1 -or CB 2 receptor antagonist may of course sometimes fail to enhance signs of pain in an experimental model because the pain score is already maximal. Conversely, it remains possible that in experiments in which SR144528 was hyperalgesic, it was acting as an inverse agonist rather than as an antagonist of endogenously released endocannabinoids.
There is evidence that cannabinoid receptor agonists can also relieve pain in humans, for example, in patients with neuropathic pain 161 and in some patients with cancer, multiple sclerosis, spinal cord injury, blepharospasm, brachial plexus damage, or pain from limb amputation. [161] [162] [163] [164] [165] [166] [167] [168] [169] Whether inhibitors of endocannabinoid metabolism or cellular uptake will also be able to induce analgesia in the clinic has still to be established.
Finally, there is evidence that CB 2 receptor inverse agonists have therapeutic potential as antiinfl ammatory agents. Thus, although there is little doubt that CB 2 receptor agonists can produce antinociception in experimental models of various kinds of pain that include infl ammatory pain, it has also been found that the CB 2 receptor inverse agonists, SR144528 and JTE-907, can inhibit carrageenan-induced mouse paw edema, 170 indicating them to be antiinfl ammatory agents, and that a third CB 2 receptor inverse agonist, Schering-Plough ' s compound 4j, inhibits immune cell migration both in vitro and in vivo. 171 , 172 There is also some evidence that although FAAH inhibitors may be effective against thermal and infl ammatory pain, they lack potential for the management of neuropathic pain. Thus, in experiments with sciatic nerve ligation models, it has been observed that FAAH − / − mice do not show signs of hypoalgesia 136 and that rats exhibit an antinociceptive response to URB597 only when this is administered at a dose well above its threshold dose for FAAH inhibition. 173 
Multiple Sclerosis
There are 2 reports that in a mouse model of multiple sclerosis, spasticity can be ameliorated both by the FAAH inhibitor, AM374, and by the inhibitors of endocannabinoid cellular uptake, AM404, VDM11, OMDM-1, and OMDM-2. 77 , 133 The model used, the chronic relapsing experimental allergic encephalomyelitis (CREAE) model, is one in which levels of anandamide and 2-arachidonoyl glycerol in both brain and spinal cord are higher than in unlesioned animals ( Table 2 ). In another model of multiple sclerosis in which mice are inoculated intracerebrally with Theiler ' s murine encephalomyelitis virus (TMEV), OMDM-1 has been found to oppose the impaired rotarod performance and reductions in spontaneous motor activity exhibited by the lesioned animals and to enhance levels of anandamide although not 2-arachidonoyl glycerol in the spinal cords of these animals. 174 There are several reasons for believing that the amelioration of spasticity induced in CREAE mice by inhibitors of FAAH or endocannabinoid cellular uptake is mediated at least in part by CB 1 and possibly also by CB 2 receptors. First, the antispastic effect of the FAAH inhibitor, AM374, has been found to be blocked by SR141716A and SR144528. 77 As AM374 is not itself expected to bind to cannabinoid receptors at the dose used, this fi nding suggests that it produced its inhibitory effect on spasticity indirectly by enhancing endocannabinoid concentrations at these receptors. Second, Pryce et al 175 have found that compared with wild-type CREAE mice, CB 1 − / − CREAE mice exhibit an earlier onset of spasticity, more immobility, residual paresis, spinal cord axonal loss and spinal neurodegeneration, and greater mortality. Third, there have been several reports that the exogenous administration to lesioned rodents of cannabinoid receptor agonists, including anandamide and 2-arachidonoyl glycerol, R -(+)-WIN55212 and ⌬ 9 -THC, the CB 1 -selective agonists, R -(+)-methanandamide and ACEA, and the CB 2 -selective agonists, JWH-133 and JWH-015, can reduce spasticity or other signs of neurological damage such as tremor and spasm 77 , 176-178 or ameliorate atonia, ataxia, gait abnormalities, paralysis, moribundity, and mortality [179] [180] [181] or improve rotarod performance. 182 These experiments were performed with rodent models of multiple sclerosis in which demyelination was induced by inoculation either with TMEV 181 , 182 or with mixtures containing CNS tissue or myelin basic protein (CREAE/EAE models). Finally, the CB 1 /CB 2 receptor agonist R -(+)-WIN55212 has been found to ameliorate clinical signs of demyelination in mice in a manner that is both stere oselective (CREAE and TMEV mice) and susceptible to antagonism by SR141716A and SR144528 (CREAE mice). 176 , 177 , 181 Evidence that cannabinoids can reduce the spasms, spasticity, or tremor of multiple sclerosis has also been obtained in clinical trials with multiple sclerosis patients 165 , 166 , 183 , 184 (also reviewed elsewhere 164 ). The degree of spasm or spasticity was either scored by the investigators using an objective measure or assessed subjectively by the patients themselves. The negative results sometimes obtained in such experiments when spasticity has been scored objectively 166 , 184 , 185 may well be a refl ection of the low sensitivity of the available methods.
Further support for the hypothesis that CREAE mice release endocannabinoids onto cannabinoid receptors and that the resultant activation of these receptors reduces spasticity comes from the fi nding that CREAE mice with mild spasticity became signifi cantly more spastic when injected with SR141716A alone or in combination with SR144528. 176 However, since these agents are both inverse agonists, it is also possible that they acted in an endocannabinoidindependent manner by reducing the extent to which cannabinoid receptors were coupling spontaneously to their effector mechanisms. Because SR141716A and SR144528 increase spasticity in CREAE mice, the fi nding that these cannabinoid receptor antagonists oppose R -(+)-WIN55212-induced reductions in the spasticity of CREAE mice should be interpreted with caution.
Results obtained with CREAE/EAE or TMEV models of multiple sclerosis also suggest that cannabinoid CB 1 or CB 2 receptor activation by exogenously administered or endogenously released agonists may oppose the progression of multiple sclerosis by slowing the neurodegenerative process, 175 reducing infl ammation, 174 , 179 , 181 , 182 and promoting remyelination. 182 
Cancer
Evidence is emerging that certain types of cancer cells overproduce anandamide and/or 2-arachidonoyl glycerol ( Table 1 ) , that these endocannabinoids act through cannabinoid receptors to inhibit cancer cell proliferation or invasion, and that this inhibitory effect can be enhanced by inhibitors of endocannabinoid metabolism or cellular uptake.
Ligresti et al 41 have detected both these endocannabinoids in biopsy specimens from human CB 1 -, CB 2 -, and FAAHexpressing colorectal tissue and found that the levels of anandamide and 2-arachidonoyl glycerol were highest in precancerous adenomatous polyps, lower in carcinomas, and lowest in normal tissue. Experiments were also performed with cultured colorectal cancer cells (CaCo-2 cells) that express CB 1 receptors and FAAH but not CB 2 receptors and contain anandamide and 2-arachidonoyl glycerol. The proliferation of these cells was inhibited by anandamide, by 2-arachidonoyl glycerol, by certain synthetic CB 1 receptor agonists, by the FAAH inhibitor N -arachidonoyl serotonin, and by the endocannabinoid cellular uptake inhibitors, VDM11 and VDM13, in a manner that was sensitive to antagonism by SR141716A. Of interest, anandamide did not inhibit the proliferation of CaCo-2 cells that had differentiated into enterocytes. These differentiated cells exhibit much lower malignancy and invasiveness, have a lower endocannabinoid content, and express more FAAH than undifferentiated CaCo-2 cells. More recently, Bifulco et al 186 showed that in vivo growth of rat thyroid tumors in athymic mice could be inhibited by intratumoral injections of VDM11 or N -arachidonoyl serotonin. The tumor content of 2-arachidonoyl glycerol was increased by both these drugs, whereas the tumor content of anandamide (and palmitoylethanolamide) was increased only by N -arachidonoyl serotonin. It was also found that in vitro proliferation of these tumor cells was inhibited both by VDM11 and by the cannabinoid receptor agonist, 2-methyl-arachidonyl-2 ' -fl uoro-ethylamide, and that this inhibition was blocked by SR141716A but not by SR144528. 2-Arachidonoyl glycerol and N -arachidonoyl serotonin, which also inhibited the in vitro proliferation of these cells, were less susceptible to antagonism by SR141716A. These fi ndings are in line with evidence from previous investigations that both cancer cell proliferation in vitro and angiogenesis, tumor growth, and metastatic spreading of cancer cells in vivo can be decreased by CB 1 receptor activation. [187] [188] [189] [190] [191] Evidence that CB 2 receptors mediate antitumor effects also exists. 188 , 190 , 191 Intriguingly, it is likely that as well as acting through CB 1 receptors to inhibit the growth of tumors in vivo and cancer cell proliferation in vitro, the anandamide analog, 2-methyl-arachidonyl-2 ' -fl uoro-ethylamide, increases expression of CB 1 receptors in these tumors and cancer cells but decreases the levels of these receptors in healthy, noncancerous cells. 187 , 189 Such an action would presumably be shared by other cannabinoid receptor agonists when these are exogenously administered or endogenously released.
In another recent investigation, Nithipatikom et al 36 found fi rst, that certain CB 1 and CB 2 -expressing human cultured androgen-independent prostate cancer cells produce 2-arachidonoyl glycerol at high concentrations, and second, that in vitro invasion of these cells could be inhibited by 2-arachidonoyl glycerol, noladin ether, R -(+)-WIN55212 and R -(+)-methanandamide, and also by 2 inhibitors of 2-arachidonoyl glycerol metabolism, MAFP and DAK. SR141716A but not SR144528 increased invasion of the prostate cancer cells and reversed the inhibitory effect of MAFP. It was also found that MAFP-induced inhibition of invasion of these cells could be enhanced by 2-arachidonoyl glycerol. Evidence has also recently been obtained from experiments with human cultured androgen-sensitive prostate cancer cells for a CB 1 and CB 2 receptor-mediated induction of apoptosis and inhibition of cell growth by R -(+)-WIN55212 and for the reduction by this cannabinoid receptor agonist of angiogenesis. 75 
Intestinal Disorders
There is evidence fi rst, that certain disorders characterized by infl ammation of the gastrointestinal tract or by diarrhea may be associated with an increase in intestinal endocannabinoid levels and/or in the expression of CB 1 receptors by myenteric neurons ( Table 3 ) , second, that the resultant hyperactivity of the endocannabinoid system ameliorates at least some of the symptoms of these diseases and, third, that this amelioration can be mimicked by CB 1 receptor agonists or enhanced by inhibitors of endocannabinoid metabolism. 192 Izzo et al 119 have obtained evidence that the endocannabinoid system acts through overexpressed CB 1 receptors to oppose cholera toxin-induced accumulation of intestinal fl uid in mice. Thus, levels of anandamide, although not of 2-arachidonoyl glycerol or palmitoylethanolamide, increased in the small intestine in response to cholera toxin as did the expression of CB 1 receptors. The intestinal fl uid accumulation induced by cholera toxin was increased by SR141716A but not by SR144528 and was reduced by CP55940 and ACEA pretreatment in a manner that was sensitive to antagonism by SR141716A but not SR144528.
Intestinal fl uid accumulation was also prevented by VDM11 in an SR141716A-sensitive manner but was unaffected by the CB 2 -selective agonist JWH-015 or by the TRPV1 antagonist capsazepine.
Results obtained by Massa et al 118 from experiments with CB 1
− / − , FAAH − / − , and wild-type mice suggest that the CB 1 component of the endogenous cannabinoid system decreases colonic infl ammation induced by intrarectal administration of 2,4-dinitrobenzene sulphonic acid (DNBS). DNBSinduced colitis was more marked in CB 1 − / − mice and less marked in FAAH − / − mice than in wild-type mice. Moreover, in wild-type mice, DNBS-induced colitis was reduced by HU-210 and enhanced by SR141716A and provoked an increase in the number of CB 1 -expressing cells in mouse colonic myenteric plexus. There is also a report that intestinal infl ammation and hypermotility induced by oral croton oil is associated with an increase in CB 1 expression level in mouse jejunum. 117 The sensitivity of croton oil-treated mice to CP55940 and cannabinol-induced inhibition of gastrointestinal transit of an orally administered charcoal suspension increased as well. High levels of anandamide and 2-arachidonoyl glycerol were detected in the small intestines of both croton oil-treated and control mice, even though FAAH activity was 2-fold higher in infl amed small intestine than in control tissue.
Mental Disorders
Giuffrida et al 54 have found that levels of anandamide but not of palmitoylethanolamide or oleoylethanolamide are markedly higher in the cerebrospinal fl uid of antipsychoticnaïve fi rst-episode paranoid schizophrenics and of schizophrenics taking " atypical " antipsychotics than in the cerebrospinal fl uid of healthy controls. In contrast, anandamide levels were not elevated in schizophrenics taking " typical " antipsychotics or in patients with dementia or affective disorders. In the antipsychotic-naïve schizophrenics there was a negative correlation between anandamide levels and severity of symptoms, a fi nding that is at least consistent with the hypothesis that anandamide has a protective role in schizophrenia. These fi ndings raise the possibility that in schizophrenia, exaggerated dopamine release onto postsynaptic D 2 -like receptors triggers release of anandamide, which then acts as a retrograde messenger to induce a CB 1 receptor-mediated attenuation of dopamine release. This chain of events would most likely be prevented by typical antipsychotics as these block D 2 -like receptors but be unaffected by atypical antipsychotics as these act mainly on 5-HT 2A receptors. Giuffrida et al 54 have also suggested that heavy cannabis use may promote psychotic episodes in vulnerable individuals by desensitizing CB 1 receptors such that the ability of endogenously released anandamide to ameliorate signs and symptoms of schizophrenia is compromised.
Marsicano et al 108 performed experiments with an aversive memory model in which mice are trained to associate a tone with a foot-shock such that once they are conditioned, they freeze when re-exposed just to the tone. Their main fi ndings were that this tone provoked an increase in anandamide and 2-arachidonoyl glycerol levels in the basolateral amygdala complex but not the medial prefrontal cortex of conditioned mice, that extinction of tone-induced freezing behavior was more pronounced in wild-type than CB 1 − / − mice, and that extinction was also impaired by SR141716A in wild-type mice. These results prompted the suggestion that the endocannabinoid system could represent a therapeutic target for the treatment of diseases associated with inappropriate retention of aversive memories or with inadequate responses to aversive situations such as post-traumatic stress disorders or phobias.
Excitotoxicity and Traumatic Brain Injury
There is some evidence from experiments with mice that anandamide is released onto CB 1 receptors during excitotoxicity ( Table 4 ) and that this release has a protective role. 128 More specifi cally, it has been found that kainic acid elevates anandamide but not 2-arachidonoyl glycerol or palmitoylethanolamide in the hippocampus, that this excitotoxin induces more severe seizures when the CB 1 receptor is genetically deleted or blocked with SR141716A, and that CB 1 receptor-expressing mice can be protected from kainic acid-induced seizures by the endocannabinoid cellular uptake inhibitor, UCM707. In addition, the data obtained suggest that the CB 1 receptors mediating this protective effect are located on principal forebrain neurons rather than on GABAergic interneurons, the likely end result of anandamide-induced activation of these receptors being inhibition of glutamate release.
There is also evidence that the endocannabinoid system may protect against the consequences of traumatic brain injury, although in this case through the release of 2-arachidonoyl glycerol. Thus, results obtained using a mouse model of closed head injury suggest that brain levels of 2-arachidonoyl glycerol increase in response to traumatic brain injury ( Table 4 ) and that when administered exogenously, this endocannabinoid can act through CB 1 receptors to reduce brain edema and improve neurobehavioral function and clinical recovery. 126 , 193 Parkinson ' s Disease It has been postulated that it may prove possible to alleviate symptoms of Parkinson ' s disease by using inhibitors of the metabolism or cellular uptake of anandamide to raise endogenous levels of this fatty acid amide so that its inhibitory effect on glutamate release from corticostriatal neurons is enhanced. 84 , 85 This hypothesis was prompted by results obtained in experiments using a rat model of Parkinson ' s disease in which nigrostriatal dopaminergic neurons are destroyed unilaterally by injecting 6-hydroxydopamine close to the substantia nigra on one side of the brain. These experiments showed that the frequency of glutamatergic spontaneous excitatory postsynaptic potentials (sEPSPs) was greater in corticostriatal slices of lesioned than of control (sham-operated) animals and that this increased rate of fi ring could be reduced by the fatty acid amide hydrolase inhibitors, PMSF and MAFP, and by the anandamide cellular uptake inhibitors, AM404 and VDM11. The direct CB 1 receptor agonist, HU-210, was found to mimic this effect of these inhibitors, while the CB 1 -selective antagonist, SR141716A prevented the effects of AM404 and PMSF. It was also found that 6-hydroxydopamine elevates levels of anandamide in the striatum but not in the cerebellum. Striatal and cerebellar levels of 2-arachidonoyl glycerol were unaffected. That inhibitors of anandamide metabolism or cellular uptake may alleviate symptoms of Parkinson ' s disease is also supported by a report that intraperitoneally administered AM404 ameliorates akinesia and sensorimotor orientation and reduces amphetamine-induced turning behavior in 6-hydroxydopamine-lesioned rats. 86 The effect of AM404 on amphetamine-induced turning behavior was abolished by the CB 1 -selective antagonist, AM251. There is also evidence from experiments with 6-hydroxydopaminelesioned rats that drugs that enhance the activity of the endocannabinoid system may have the capacity to suppress or prevent unwanted dyskinesias that are often induced in parkinsonian patients by the therapeutic agent, L-dihydroxyphenylalanine (L-DOPA). 87 Results from other investigations have raised the possibility that symptoms of Parkinson ' s disease could be alleviated by CB 1 receptor antagonists. Thus there are 2 reports from the E642 same laboratory that the akinesia, sensorimotor orientation, and asymmetric motor behavior exhibited by rats with 6-hydroxydopamine-induced unilateral nigral lesions can be signifi cantly attenuated by SR141716A or AM251 when these are given either systemically or unilaterally into the striatum or globus pallidus on the lesioned side of the brain. 194 , 195 An additional fi nding, that inhibitory effects of systemic SR141716A or AM251 on amphetamine-induced asymmetric motor behavior could be prevented by AM404, was taken as evidence for the presence of a CB 1 receptormediated modulation of nigrostriatal dopaminergic tone in the lesioned animals and also suggests that these antagonists were acting to reduce this tone. SR141716A and AM251 were most effective when given to rats exhibiting particularly severe behavioral signs of nigral degeneration, suggesting that cannabinoid CB 1 receptor antagonists might be useful for treating advanced stages of Parkinson ' s disease in humans. 195 That CB 1 receptor antagonists could be used for the management of Parkinson ' s disease has also been proposed by Lastres-Becker et al. 61 This suggestion was prompted by results they obtained in experiments with tissue both from parkinsonian patients and from marmosets lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). More specifi cally, they found that CB 1 receptors in parkinsonian and MPTP-lesioned basal ganglia bind more [ 3 H]CP55940 and exhibit greater coupling effi ciency than control tissue and that these changes were less marked in the basal ganglia of MPTP-treated animals that had been exposed to L-DOPA. It is noteworthy, however, that Meschler et al 196 have reported that SR141716A does not alleviate motor defi cits induced by MPTP in cynomolgus monkeys.
Clearly no fi rm conclusions can yet be drawn about the role of the endocannabinoid system in Parkinson ' s disease or about the extent to which modulation of this system with drugs could alleviate undesirable symptoms associated either with the disease itself or with the established antiparkinsonian drug, L-DOPA.
Cardiovascular Disorders
There is evidence that anandamide and 2-arachidonoyl glycerol are major contributors to hypotension associated with hemorrhagic, septic, or cardiogenic shock. Thus fi rst, it has been found that hypotension induced in anaesthetized rats by bleeding, by acute myocardial infarction, or by intravenous administration of bacterial lipopolysaccharide (LPS), a major pathogenic factor in septic shock, can be opposed by SR141716A or AM281, whereas exogenous 2-arachidonoyl glycerol administration induces hypotension in anaesthetized normotensive animals. 113 , 116 , 197 , 198 Second, there are reports that macrophages obtained from the blood of rats that are normotensive or in hemorrhagic shock can synthesize anandamide 197 and that in vitro administration of LPS elevates levels of 2-arachidonoyl glycerol in rat platelets and of anandamide in rat and mouse macrophages and human lymphocytes [113] [114] [115] ( Table 3 ) . There is also a report that anandamide and 2-arachidonoyl glycerol are detectable in monocytes and platelets isolated from rats after acute myocardial infarction but not in cells obtained from control animals 116 ( Table 3 ) . Third, blood from hemorrhaged rats and cells isolated from rat blood after acute myocardial infarction or onset of LPS-induced hypotension can cause prolonged hypotension in anaesthetized normotensive rats. 113 , 116 , 197 This hypotension was found to be considerably attenuated or completely abolished by SR141716A, pointing to an involvement of CB 1 receptors. Moreover the ability of LPS to increase anandamide levels in mouse macrophages in vitro can be enhanced by the nonselective FAAH inhibitor, PMSF, and a much greater decrease in blood pressure can be elicited by LPS-treated peritoneal macrophages when these cells are obtained from FAAH − / − rather than from FAAH +/+ mice. 114 It is possible that CB 1 -mediated hypotension may aid survival in hemorrhagic and cardiogenic shock. Thus, as well as attenuating hypotension induced in urethane-anaesthetized rats by bleeding or acute myocardial infarction, SR141716A has been found to reduce the survival time of these animals. 116 , 197 Conversely, survival of hemorrhaged rats is signifi cantly increased by the cannabinoid receptor agonists, ⌬ 9 -THC and HU-210. 197 In LPS-treated rats, however, survival can be improved both by ⌬ 9 -THC and by SR141716A or AM281. 113 , 198 There is also evidence that CB 1 receptors may mediate a protective hypotensive effect in spontaneously hypertensive rats. 111 These are animals in which it has been found that blood pressure is elevated by SR141716A and reduced by the FAAH inhibitor, URB597, and by 2 inhibitors of endocannabinoid cellular uptake, AM404 and OMDM-2. The blood pressure of normotensive rats was not affected by any of these drugs. Compared with normotensive rats, spontaneously hypertensive rats also express more CB 1 receptors in the myocardium and aorta ( Table 3 ) and show greater sensitivity to anandamide-and HU-210-induced hypotension. 111 However, FAAH expression is higher and myocardial levels of anandamide (but not of 2-arachidonoyl glycerol) are lower in spontaneously hypertensive rats than in normotensive animals ( Table 3 ) , raising the possibility that the endocannabinoid system may protect against hypertension in this animal model by increasing " target organ sensitivity " rather than by increasing endocannabinoid levels. 111 Finally, it is possible that the endocannabinoid system may protect against atherosclerosis as fi rst, CB 2 receptors are expressed by macrophages and T-lymphocytes within atherosclerotic plaques of human and mouse diseased arteries ( Table 1 ) , and second, there is evidence that when E643 administered orally at 1 mg/kg per day, ⌬ 9 -THC can act through CB 2 receptors to produce a signifi cant inhibition of atherosclerosis progression in mice. 71 
THERAPEUTIC STRATEGIES
It is clear from the preceding 2 sections of this review that the endocannabinoid system is thought to upregulate in some disorders and that one consequence of this upregulation may be the alleviation of symptoms or even the removal of the underlying causes of some of these symptoms. This section begins by considering how direct agonists might best be used in the clinic to mimic protective effects of the endocannabinoid system. It then goes on to discuss some alternative potential strategies that would augment these protective effects indirectly by potentiating endogenously released endocannabinoids through effects on their metabolism, cellular uptake, or receptors.
Direct Cannabinoid Receptor Agonists
Two CB 1 /CB 2 cannabinoid receptor agonists have been licensed for clinical use in some countries for several years. These are dronabinol (Marinol; ⌬ 9 -THC) and the synthetic ⌬ 9 -THC analog, nabilone, which can be prescribed as antiemetics (both drugs) and to stimulate appetite (dronabinol). 199 Both these drugs are administered orally. In addition, Sativex, a medicine that contains ⌬ 9 -THC and cannabidiol, was recently licensed for the management of neuropathic pain associated with multiple sclerosis. 199 , 200 A signifi cant number of patients also claim to obtain relief from symptoms of multiple sclerosis and, indeed, from various kinds of chronic pain, from arthritis and/or from neuropathy by self-medicating with cannabis. 201 , 202 As to novel synthetic CB 1 /CB 2 or CB 2 cannabinoid receptor agonists that exhibit antinociceptive activity in animal models of pain, there are as yet no clinical data, although several of these have been synthesized and investigated preclinically by drug companies (eg, by GlaxoSmithKlein 150 , 151 and by Bayer 203 ).
A strong case can be made for using cannabinoid receptor direct agonists in the clinic now, particularly to relieve neuropathic pain and to ameliorate the spasms and spasticity of multiple sclerosis. However, a strong argument can also be made for conducting research directed at establishing how in the longer term the benefi t-to-risk ratio of drugs that rely on the activation of cannabinoid receptors for their soughtafter clinical effects can be improved. Some potential strategies for meeting this objective are listed below.
• Exploit the ability of cannabinoid CB 1 receptors expressed outside the central nervous system to mediate sought-after effects such as pain relief (reviewed elsewhere 139 , 140 ), the inhibition of cancer cell proliferation and spread ( Cancer section) and the amelioration of certain intestinal and cardiovascular disorders ( Intestinal Disorders and Cardiovascular Disorders sections). One possibility would be to administer CB 1 receptor agonists transdermally and, indeed, there is already evidence that this strategy is effective in human subjects for reducing experimental pain. 204 , 205 A second possibility would be to develop CB 1 receptor agonists that do not readily cross the blood-brain barrier.
• Exploit the ability of cannabinoid CB 1 receptors expressed in the spinal cord to mediate pain relief by administering CB 1 receptor agonists intrathecally (reviewed elsewhere 139 , 140 ). This is already an accepted procedure that is, for example, used for the self-administration of baclofen by some multiple sclerosis patients.
• Exploit the ability of cannabinoid CB 2 receptors to mediate pain relief by administering a CB 2 -selective agonist ( Pain section). This would of course avoid all unwanted consequences of CB 1 receptor activation, provided the dose of agonist used was not excessive.
• Exploit the ability of a low dose of a cannabinoid receptor agonist such as ⌬ 9 -THC both to interact synergistically with a low dose of an opioid such as morphine or codeine for the production of analgesia and to oppose onset of opioid tolerance (reviewed elsewhere 139 , 206 ). The success of this approach will depend on the extent to which these drugs interact synergistically in the clinic to produce undesirable effects. It is worth noting that there is already a report that orally-administered ⌬ 9 -THC had a " morphine-sparing effect " for a patient with severe abdominal pain. 207 • Exploit the apparent ability of drugs such as the nonpsychotropic cannabinoid, cannabidiol, to reduce some of the undesirable effects of CB 1 receptor activation and perhaps also provide additional benefi cial effects. 208 Indeed, the licensed medicine, Sativex, contains both cannabidiol and ⌬ 9 -THC. 199 , 200 For some clinical applications it may be advantageous to combine 2 or more of these potential strategies. For example, neuropathic pain might sometimes best be relieved by targeting both CB 1 and CB 2 receptors, perhaps by administering a CB 2 receptor agonist together with a CB 1 agonist that does not readily cross the blood-brain barrier.
Any agonist that possesses CB 1 or CB 2 selectivity is expected to target CB 1 or CB 2 receptors selectively only within a fi nite dose range and to activate both receptor types when administered at a dose that lies above this range. Such a fi nding has, for example, been made with the CB 2 -selective agonist GW405833. 151 For any particular agonist, the width of its CB 1 or CB 2 selectivity window will of course be affected by the CB 1 to CB 2 receptor ratios of the tissues in which sought-after (or unwanted) effects are induced by CB 1 or CB 2 receptor activation. It is noteworthy, therefore, that not all tissues express CB 1 and CB 2 receptors in equal numbers in health and that there is also evidence that disparate changes in CB 1 and CB 2 expression levels may be induced in some cells or tissues either pathologically or pharmacologically. Consequently, when an agonist that binds more readily either to CB 1 or to CB 2 receptors is administered to patients, it is likely that the CB 1 or CB 2 selectivity of this ligand will not be the same in all tissues that express both receptor types and also that any selectivity will be lost when a certain dose level is exceeded. It is also important to bear in mind that there is evidence that some cannabinoid receptor agonists can activate non-CB 1 , non-CB 2 pharmacological targets. Since cannabinoid receptor agonists differ in the extent to which they appear to interact with each of these proposed additional targets, it follows that some ligands with apparently similar abilities to activate CB 1 and/or CB 2 receptors are likely to possess different pharmacological profi les.
Indirect Cannabinoid Receptor Agonists
Existing indirect cannabinoid receptor agonists are all drugs that delay the removal of endocannabinoid molecules from their sites of action. • Inhibition of FAAH is likely to augment anandamide levels not only at cannabinoid receptors but also at its other targets, for example the vanilloid TRPV1 receptor and the putative abnormal cannabidiol receptor, if this endocannabinoid is being released onto these other targets.
• Inhibition of FAAH is also likely to augment levels of certain other endogenous fatty acid amides when these are undergoing release. These amides include 2 cannabinoid receptor ligands, oleamide which might well increase drowsiness if its levels in the brain are elevated, 209 and N -arachidonoyl dopamine. They also include ligands that do not readily bind to cannabinoid receptors such as palmitoylethanolamide, which produces antinociception possibly by acting on peripheral " CB 2 -like " receptors ( Pain section), oleoylethanolamide, which is thought to stimulate fat utilization through activation of PPAR-␣ receptors, and N -arachidonoyl glycine, which is itself a FAAH inhibitor that can induce antinociception in animals when administered exogenously.
• A FAAH inhibitor is not expected to enhance the ability all endocannabinoids to induce symptom relief. Thus, some putative endocannabinoids are metabolically stable (eg, noladin ether) or are metabolized mainly by enzymes other than FAAH (eg, 2-arachidonoyl glycerol).
• Inhibition of FAAH may increase the extent to which the fatty acid amide substrates of this enzyme are degraded by other enzymes. For example, anandamide is known also to be metabolized by PAA, by cyclo-oxygenase-2, by lipoxygenases, and by cytochrome P450. Moreover, as there is evidence E645 that the lipoxygenase metabolites of anandamide are more potent than their parent compound as TRPV1 agonists, 210 it is possible that some patients receiving a FAAH inhibitor would experience either hyperalgesia due to TRPV1 activation or analgesia resulting from TRPV1 desensitization.
Turning now to inhibitors of endocannabinoid cellular uptake, there is evidence that these too have therapeutic potential. This comes from experiments in which such inhibitors have been found to decrease cancer cell proliferation and tumor growth and to ameliorate symptoms in animal models of pain, multiple sclerosis, excitotoxicity, Parkinson ' s disease, cholera toxin-induced diarrhea, and hypertension. As to MAG lipase inhibitors, any assessment of their therapeutic potential must await the development of suitable compounds, there being a need for compounds that inhibit MAG lipase at doses that do not also inhibit FAAH or interact directly with cannabinoid receptors or with other pharmacological targets that might compromise their selectivity. There is also an urgent need for an allosteric enhancer of the CB 1 receptor that exhibits appropriate effi cacy and selectivity. Such an enhancer will most likely differ from a FAAH inhibitor in the following ways:
• by possessing the ability to produce greater symptom alleviation in at least some disorders through the augmentation of CB 1 receptor-mediated responses to all endocannabinoids no matter how their actions are terminated and
• by lacking the ability to augment the activation by anandamide or other fatty acid amides of targets other than CB 1 receptors.
CANNABINOID RECEPTOR EXPRESSION LEVELS AND SIGNALING
There is evidence that upregulation of the endocannabinoid system leading to an alleviation of symptoms can take the form not only of enhanced endocannabinoid release but also of an increase in cannabinoid receptor density or coupling effi ciency in tissues in which these receptors mediate symptom relief or inhibition of disease progression when activated by endogenously released endocannabinoids or by exogenously administered cannabinoid receptor agonists. Indeed, results from rat experiments suggest that the endocannabinoid system may protect against hypertension through an increase in CB 1 receptor density/sensitivity rather than through an increase in endocannabinoid release ( Cardiovascular Disorders section). Other seemingly protective increases in CB 1 and/or CB 2 receptor density or coupling effi ciency have been detected in human and mouse atherosclerotic plaques, in human prostate cancer cells, and in animal models of Parkinson ' s disease, neuropathic pain, diarrhea, intestinal infl ammation, and colitis.
It has been reported that cannabinoid receptor expression is higher in some cancer cells than in normal cells 75 , 187 , 189 and also that it sometimes correlates with the degree of cancer cell malignancy. 131 It will be important to identify other disorders in which cannabinoid receptor upregulation is confi ned entirely or mainly to tissues in which activation of cannabinoid receptors is expected to alleviate symptoms or to inhibit disease progression. This is because such a pattern of receptor upregulation may well improve the selectivity of cannabinoid receptor agonists by enhancing their potency for the production of sought-after effects more than their potency for the production of unwanted effects. Selectivity improvements resulting from an uneven cannabinoid receptor upregulation of this kind are expected to be most evident for partial agonists such as ⌬ 9 -THC and cannabinol. Thus although an increase in receptor density will augment the potencies of both full and partial agonists, it will often also increase the size of the maximal response to a partial agonist without affecting the maximal response to a full agonist. This difference between the pharmacology of full and partial agonists can be seen in results from experiments with cannabinol and CP55940 in which an increase in the intestinal expression of CB 1 receptors (and intestinal infl ammation) had been induced in mice by oral croton oil and in which the measured response was cannabinoid-induced CB 1 receptor-mediated inhibition of upper gastrointestinal transit of a charcoal suspension. 117 Thus, it was found that this increase in CB 1 expression level was accompanied not only by a leftward shift in the log dose-response curve of cannabinol but also by an increase in the size of the maximal effect of this partial agonist. In contrast, the higher efficacy agonist, CP55940, exhibited an increase in its potency but no change in its maximal effect.
The upregulation of a subpopulation of cannabinoid receptors that alleviates symptoms or inhibits disease progression when activated should of course also augment protective effects of endogenously released endocannabinoids and hence of FAAH inhibitors and other types of indirect agonist. For anandamide, cannabinoid receptor upregulation is likely to produce an increase in maximal effect as well as potency as this endocannabinoid is a CB 1 and CB 2 receptor partial agonist. On the other hand, 2-arachidonoyl glycerol would be expected to exhibit only an increase in potency as it has been found in several investigations to exhibit much higher CB 1 and CB 2 receptor effi cacy than anandamide ( Endocannabinoids section).
Tolerance can develop to CB 1 receptor agonists and there is evidence that this is often caused by a reduction in CB 1 receptor density or signaling. 211 Consequently, it is tempting to speculate that if a particular disease causes an increase E646 in cannabinoid receptor density or signaling this receptor upregulation may oppose the ability of endogenously released or exogenously administered cannabinoid receptor agonists to induce tolerance. If such receptor upregulation is restricted largely to receptors that mediate an alleviation of symptoms or an inhibition of disease progression, then patients would be protected from the development of tolerance to sought-after but not to unwanted effects of a cannabinoid receptor agonist in a manner that would lead to a broadening of the agonist ' s therapeutic window in response to its repeated administration. There is already good evidence that tolerance develops less readily to some effects of cannabinoid receptor agonists than to others (reviewed elsewhere 212 ) and, indeed, that some sought-after therapeutic effects of a CB 1 receptor agonist may be more resistant to tolerance development than some of its unwanted effects. 213 CB 1 receptor agonists may also sometimes widen their own therapeutic windows by inducing a selective increase in the density of CB 1 receptors that are mediating a sought-after effect such as inhibition of the growth and proliferation of cancer cells.
DAMAGING UPREGULATION OF THE ENDOCANNABINOID SYSTEM?
There are some disorders in which the endocannabinoid system appears to upregulate to induce undesirable symptoms, an indication that this system may sometimes malfunction. For example, it has been postulated that upregulation of the endocannabinoid system can
• impair fertility in some women as there are reports (1) that FAAH activity and expression fall in the lymphocytes of some women who miscarry or who fail to become pregnant after in vitro fertilization (IVF) and embryo transfer, (2) that this fall is accompanied in the IVF-embryo transfer group of women by a corresponding rise in blood anandamide 65 , 66 (see also • contribute toward obesity in some individuals as, for example, it has been found that hypothalamic levels of anandamide and/or 2-arachidonoyl glycerol are raised in obese db/db and ob/ob mice and fa/fa rats ( Table 2 ) , that CB 1 receptor expression levels are elevated in the adipose tissue of obese fa/fa rats ( Table 2 ), and that SR141716A reduces the food intake of db/db and ob/ob mice, reduces the body weight of db/db mice, and decreases the food intake, body weight, and waist circumference of obese humans 102 , 215 ;
• contribute toward osteoporosis and other diseases in which there is bone loss, as bone mineral density is greater in CB 1 − / − mice than in wild type animals, as ovariectomy does not induce bone loss in CB 1 − / − mice, as AM251 and SR144528 protect against ovariectomy-induced bone resorption, as CB 1 and CB 2 receptor antagonists/inverse agonists signifi cantly inhibit evoked osteoclast formation in CB 1 and CB 2 receptor-expressing mouse bone marrow cultures, and as anandamide and CP55940 can stimulate osteoclast formation in these cultures 216 ;
• contribute toward the production of cerebral injury in stroke as unilateral ischemia/reperfusion injury induced in rats by transient middle cerebral artery occlusion has been reported to be associated with an elevation of whole brain anandamide and as infarct volume and neurological impairment in lesioned rats were both found to be less after pretreatment with selective CB 1 receptor antagonists 123 (see also Table 4 );
• contribute toward the life-threatening excessive hypotension of endotoxaemic shock triggered by advanced liver cirrhosis 68 , 112 ( Table 3 ) or by the cemented hip arthroplasty procedure 76 ( Table 1 ) (but may aid survival in hemorrhagic, septic, and cardiogenic shock);
• contribute toward the development of hyperrefl exia and hyperalgesia during cystitis as it has been found that urinary bladder levels of anandamide increase in a rat model of this disorder ( Table 2 ) and that refl ex activity increased both when anandamide was applied to healthy bladders and when the FAAH/anandamide cellular uptake inhibitor, palmitoylisopropylamide, was applied to healthy or infl amed bladders 101 ;
• contribute toward intestinal infl ammation in ileitis as there is a report that ileal levels of anandamide (and 2-arachidonoyl glycerol) increase in a rat model of this disorder ( Table 3 ) , as infl ammation and fl uid accumulation in the rat ileum increase in response to intraluminal injection of either of these endocannabinoids, and as intraluminal injections of the FAAH/MAG lipase inhibitors, PMSF or MAFP, augment intra-ileal fl uid accumulation induced by Clostridium diffi cile toxin A 120 ;
• contribute toward intestinal hypomotility in paralytic ileus as reductions in mouse intestinal motility induced by peritoneal irritation with acetic acid has been shown to be counteracted by SR141716A (although not by SR144528), to be exacerbated by the anandamide cellular uptake inhibitor, VDM11, in an SR141716A-sensitive manner, and to be accompanied in the small intestine by increases E647 in anandamide levels and in the neural density of CB 1 receptor immunoreactivity 121 (see also Table 3 ).
Endocannabinoids appear to produce many of their unwanted effects by interacting with cannabinoid CB 1 receptors. Thus, results from animal experiments suggest that endocannabinoids act on these receptors to induce (1) impairment of embryo implantation and development (reviewed elsewhere 214 ), (2) increases in food intake and body weight associated with obesity, 102 (3) cerebral injury in stroke, 123 (4) hypotension in liver cirrhosis, 68 and (5) intestinal hypomotility in paralytic ileus. 121 As to the CB 2 component of the endocannabinoid system, evidence is emerging that this too may sometimes induce unwanted effects by promoting infl ammation in a manner that can be counteracted by CB 2 receptor inverse agonism. There are also unwanted effects of the endocannabinoids that appear to be mediated by TRPV1 rather than CB 1 or CB 2 receptors. These are urinary bladder hyperrefl exia in cystitis, and intestinal infl ammation and fl uid accumulation in ileitis. 101 , 120 In these instances the undesirable effects can be attenuated by TRPV1 receptor antagonism but not CB 1 receptor antagonism which, indeed, was found to exacerbate anandamide-induced bladder hyperrefl exia. Clearly then, there may be a place in the clinic for CB 1 and TRPV1 receptor antagonists and possibly also for CB 2 receptor inverse antagonists. Indeed, the CB 1 receptor antagonist, SR14171A (rimonabant; Acomplia), is already in the fi nal stages of development as an anti-obesity agent. 215 Selective inhibitors of endocannabinoid biosynthesis, activators of endocannabinoid-metabolizing enzymes, and allosteric antagonists of the CB 1 receptor also have therapeutic potential for the management of some disorders with symptoms that are induced by endogenously released cannabinoids. However, such drugs have yet to be developed.
FUTURE DIRECTIONS
There is no doubt that the endocannabinoid system upregulates both in response to certain pathological changes or to stress and during normal physiological events such as aging, feeding, fasting, and exercise. There is also good evidence that this upregulation can take the form of an increase both in the release of endocannabinoid molecules onto their receptors and in the density or coupling effi ciency of some of these receptors. Often, this upregulation appears to protect the organism from unwanted symptoms or even to slow the progression of a disease. However, there is also evidence that upregulation of the endocannabinoid system can sometimes trigger unwanted symptoms, an indication that this system has its own pathology and possibly also that it is sometimes infl uenced detrimentally by pathological events taking place in some other system from which it receives input.
As to the future, it will be important to obtain a more complete list of pathological processes that are modulated by the endocannabinoid system and to determine for each of these processes whether this modulation has desirable or undesirable consequences. It will also be important to establish both the nature of this modulation and the extent to which it is confi ned to tissues in which cannabinoid receptor activation affects symptoms or disease progression. This in turn will help identify the best pharmaco logical strategy for the management of any particular disorder in which the endocannabinoid system has upregulated, be this to administer a CB 1 and/or CB 2 receptor agonist or antagonist that does or does not readily cross the blood-brain barrier, a CB 1 and/or CB 2 receptor agonist intrathecally or directly to some other site outside the brain, a partial CB 1 and/or CB 2 receptor agonist rather than a full agonist, a CB 1 and/or CB 2 receptor agonist together with a noncannabinoid, an inhibitor or activator of endocannab inoid biosynthesis, cellular uptake or metabolism, an allosteric modulator of the CB 1 receptor, or a CB 2 receptor inverse agonist. Other important objectives for future research are
• to obtain a more complete understanding of the processes that determine the biosynthesis, release, and fate of endocannabinoids,
• to identify those drugs that are best at modulating these processes selectively or at producing selective allosteric enhancement or antagonism of cannabinoid receptors,
• to characterize the pharmacology of these drugs and to test them in the clinic,
• to investigate the extent to which tolerance develops over time to protective effects of endocannabinoids when these are released by themselves or in the presence of drugs that augment the tissue levels of released endocannabinoids,
• to establish in greater detail the part played by non-CB 1 , non-CB 2 targets in both the protective and the undesirable consequences of endogenous cannabinoid release, and
• to gain a better understanding of the part played by spinal or peripheral CB 1 and CB 2 receptors in modulating the symptoms and progression of particular diseases.
Finally, since the completion of this review, evidence has emerged that the orphan G protein-coupled receptor, GPR55, is a cannabinoid receptor, 217 , 218 prompting a need for research that will identify the physiological and/or pathological roles of this receptor and characterize its pharmacology. The discovery of a selective MAG lipase inhibitor, URB602, has also just been announced. 219 
